AZNAstraZenecaRunning, no new patients
Study of Capivasertib + Docetaxel vs Placebo + Docetaxel as Treatment for Metastatic Castration Resistant Prostate Cancer (mCRPC)
Prostate Cancer
0Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
No warning signs right now. That's why the score is 0.
Score over time
- Stage
- Phase 3
- Patients
- 1,035 (final count)
- Started
- Mar 25, 2022
- Main results expected
- Mar 4, 2026
- Fully finished
- Mar 4, 2026
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Overall Survival (OS) in the overall population
Measured over: up to approximately 46 months
Radiographic Progression-free Survival (rPFS) in the overall population
Measured over: up to approximately 37 months
Changes Tremor has spotted
No changes since Tremor started watching this trial.
Show details (technical version)
Score inputs
- none
Raw record changes
- none yet
Trial ID NCT05348577 · record last updated 2025-01-27 · checked 2026-11-09 15:47 UTC